Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2019
Reporting Period: Event date of September 24, 2019
The Company, an emerging growth company, reported a significant clinical milestone regarding its product DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Milestones
- Event: Dosed the first patients in a Phase 3 clinical trial of DEXTENZA for the treatment of symptoms of allergic conjunctivitis (AC).
- Trial Design: U.S.-based, multi-center, 1:1 randomized, double-masked, placebo-controlled trial.
- Enrollment: Intends to enroll approximately 80 subjects.
- Methodology: Uses the Ophthalmic Research Associates' modified Conjunctival Allergen Challenge (Ora-Cac) Model to assess ocular itching over a 30-day period.
- Significance: This is the third Phase 3 clinical trial in AC conducted by the Company.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Regulatory Path: If successful, the Company plans to submit a supplemental New Drug Application (sNDA) to the FDA for ocular itching associated with AC.
- Data Timeline: Topline data from this trial are anticipated in the first half of 2020.
Risks and Contingencies
- Contraindications: DEXTENZA is contraindicated in patients with active corneal, conjunctival, or canalicular infections.
- Adverse Reactions: Prolonged corticosteroid use may result in glaucoma, optic nerve damage, and visual defects. Steroids may increase the hazard of secondary infections and delay wound healing post-cataract surgery.
- Common Adverse Events: Anterior chamber inflammation (10%), elevations in intraocular pressure (6%), and headache (1%).
Investor Verification Checklist
- Verify the enrollment progress and completion date of the 80-subject Phase 3 trial.
- Monitor the anticipated release of topline data in the first half of 2020.
- Review the Company's cash runway and capital requirements, as this filing does not disclose current liquidity or debt levels.
- Assess the regulatory feedback from the FDA regarding the potential supplemental New Drug Application for allergic conjunctivitis.